Shane Darke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shane Darke has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Johan Duflou
National Drug and Alcohol Research Centre University of New South Wales Sydney Australia
46 shared publications - Joanne Ross
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
34 shared publications Michael Farrell
National Drug & Alcohol Research Centre, University of New South Wales, NSW, Australia
31 shared publications- Maree Teesson
The Matilda Centre for Research in Mental Health and Substance Use The University of Sydney Sydney Australia
25 shared publications - Julia Lappin
Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, Australia
24 shared publications - Michelle Torok
Black Dog Institute, University of New South Wales, Sydney, New South Wales, Australia
22 shared publications
Latest Publications
- Open Access
Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology
Aims: To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in case characteristics of known fatal cases in the period pre‐COVID (2016–2019), COVID (2020–2022) and post‐COVID (2023–2025). Design: Retrospective study of fatal MDMA‐related poisonings in Australia retrieved from the NCIS, 2016–2025 [Correction added on 28 September 2026, after first online publication: In the previous sentence, “NDIS” has been changed to “NCIS”.]. Setting: Australia‐wide. Cases: 217 cases of fatal MDMA‐related poisoning. Measurements: Population rates, case characteristics, circumstances of death, toxicology, major autopsy findings. Results: There was a statistically significant increasing trend in the population rate over 2016–2019 [annual percentage change (APC) = 61.52], and a statistically significant decreasing trend over 2019–2023 (APC = −26.72). The mean age was 33.5 years, and males comprised 170 cases (78.3%). In 179 cases (82.5%) the cause of death was attributed to multiple drug toxicity. The fatal incident occurred in a private setting in 171 cases (78.8%), with 16 (7.4%) occurring at a music festival. The median MDMA blood concentration was 0.41 mg/l (range 0.00–25.0 mg/l). Cases in which death was attributed solely to MDMA toxicity had a higher median MDMA concentration than multiple drug toxicity deaths (1.7 vs. 0.30 mg/l). Psychoactive drugs other than MDMA were detected in 199 cases (91.7%), most commonly other psychostimulants (147, 67.7%) and opioids (98, 45.2%). Cardiomegaly was diagnosed in 33 cases (16.6%) in which the heart was examined, and severe coronary artery disease in 27 (13.6%). There were no statistically significant differences across time periods in age, sex, substance use issues, injecting drug use, intentionality, MDMA concentrations or diagnoses of cardiomegaly. Summary: While death rates in Australia from methylenedioxymethamphetamine‐related poisoning have declined from 2019, case characteristics have remained relatively stable.
Open AccessMethylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology
Aims: To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in case characteristics of known fatal cases in the period pre‐COVID (2016–2019), COVID (2020–2022) and post‐COVID (2023–2025). Design: Retrospective study of fatal MDMA‐related poisonings in Australia retrieved from the NCIS, 2016–2025 [Correction added on 28 September 2026, after first online publication: In the previous sentence, “NDIS” has been changed to “NCIS”.]. Setting: Australia‐wide. Cases: 217 cases of fatal MDMA‐related poisoning. Measurements: Population rates, case characteristics, circumstances of death, toxicology, major autopsy findings. Results: There was a statistically significant increasing trend in the population rate over 2016–2019 [annual percentage change (APC) = 61.52], and a statistically significant decreasing trend over 2019–2023 (APC = −26.72). The mean age was 33.5 years, and males comprised 170 cases (78.3%). In 179 cases (82.5%) the cause of death was attributed to multiple drug toxicity. The fatal incident occurred in a private setting in 171 cases (78.8%), with 16 (7.4%) occurring at a music festival. The median MDMA blood concentration was 0.41 mg/l (range 0.00–25.0 mg/l). Cases in which death was attributed solely to MDMA toxicity had a higher median MDMA concentration than multiple drug toxicity deaths (1.7 vs. 0.30 mg/l). Psychoactive drugs other than MDMA were detected in 199 cases (91.7%), most commonly other psychostimulants (147, 67.7%) and opioids (98, 45.2%). Cardiomegaly was diagnosed in 33 cases (16.6%) in which the heart was examined, and severe coronary artery disease in 27 (13.6%). There were no statistically significant differences across time periods in age, sex, substance use issues, injecting drug use, intentionality, MDMA concentrations or diagnoses of cardiomegaly. Summary: While death rates in Australia from methylenedioxymethamphetamine‐related poisoning have declined from 2019, case characteristics have remained relatively stable.
- Open Access
Holistic approach to substance‐induced psychosis
- Open Access
- 22 March 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 19, 100434
The toxicology and characteristics of fatal new psychoactive stimulant and hallucinogen-related poisonings in Australia, 2000–2025
- 22 March 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 19, 100434
Open AccessThe toxicology and characteristics of fatal new psychoactive stimulant and hallucinogen-related poisonings in Australia, 2000–2025
- Open Access
- 18 February 2026
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 282, 113085
Changing characteristics in the 2020s of fatal ‘novel’ benzodiazepine toxicity cases in Australia
- 18 February 2026
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 282, 113085
Open AccessChanging characteristics in the 2020s of fatal ‘novel’ benzodiazepine toxicity cases in Australia
Trends in gamma‐hydroxybutyrate use, harms and treatment in Australia, 2013 to 2024
Background and Aims: There is significant concern about potential rising harms from gamma‐hydroxybutyrate (GHB) but an absence of studies internationally synthesising data across indicators to identify changes in harms and broader patterns of use. This paper contributes to addressing this gap by measuring national trends in GHB use, harms and treatment in Australia. Design, setting, and cases: Triangulation of indicators (2013–2024) from Australian triennial population surveys; annual interviews with cross‐sectional non‐representative samples of people who use illicit stimulants or who inject drugs; and administrative data on GHB‐related hospitalisations, GHB‐related deaths, and treatment episodes where GHB was the principal drug of concern. Measurements: Annual trend data were analysed using Joinpoint regression. Survey data were modelled as the annual percent change in the proportion reporting lifetime, past 12‐month, and past 6‐month use, depending on the survey. Administrative data were modelled as the annual percent change in crude rates per 100 000 population. Findings: Lifetime and past 12‐month GHB use in the general population remained below 1.2% and 0.2% respectively, but the latter increased from 0.07% in 2013 to 0.19% in 2022–2023 (annual percent change [APC] 9.3; 95% confidence interval [CI]: 5.2, 13.2). The percentage of people who use illicit stimulants reporting past 6‐month use increased from 5.7% in 2013 to 7.3% in 2017 (APC 11.6; 95%CI: 0.2, 52.9) and from 5.4% in 2019 to 11.5% in 2024 (APC 17.8; 95%CI: 5.9, 41.1). The proportion of people who inject drugs reporting use varied between 7.2% and 17.5% over the short period studied (2020–2024). There were statistically significant increases in GHB‐related hospitalisations from 5.3 in 2012–13 to 19.1 per 100 000 people in 2022–23 (APC 19.0; 95%CI: 11.9, 31.1) and GHB‐related deaths from 0.02 in 2013 to 0.24 per 100 000 people in 2022 (APC 36.5; 95%CI: 27.2, 58.1). Treatment episodes also increased across the period, from 0.07 in 2012–13 to 6.0 episodes per 100 000 people in 2020–21 (APC 97.3; 95%CI: 83.5, 830.9), with no subsequent statistically significant change (8.4 per 100 000 people in 2022–23). Conclusions: Gamma‐hydroxybutyrate use, harms and treatment engagement increased in Australia from 2013 to 2024. These findings highlight a need to implement acceptable, tailored prevention and harm reduction strategies for key populations, and implement stronger monitoring efforts nationally and internationally.
Trends in gamma‐hydroxybutyrate use, harms and treatment in Australia, 2013 to 2024
Background and Aims: There is significant concern about potential rising harms from gamma‐hydroxybutyrate (GHB) but an absence of studies internationally synthesising data across indicators to identify changes in harms and broader patterns of use. This paper contributes to addressing this gap by measuring national trends in GHB use, harms and treatment in Australia. Design, setting, and cases: Triangulation of indicators (2013–2024) from Australian triennial population surveys; annual interviews with cross‐sectional non‐representative samples of people who use illicit stimulants or who inject drugs; and administrative data on GHB‐related hospitalisations, GHB‐related deaths, and treatment episodes where GHB was the principal drug of concern. Measurements: Annual trend data were analysed using Joinpoint regression. Survey data were modelled as the annual percent change in the proportion reporting lifetime, past 12‐month, and past 6‐month use, depending on the survey. Administrative data were modelled as the annual percent change in crude rates per 100 000 population. Findings: Lifetime and past 12‐month GHB use in the general population remained below 1.2% and 0.2% respectively, but the latter increased from 0.07% in 2013 to 0.19% in 2022–2023 (annual percent change [APC] 9.3; 95% confidence interval [CI]: 5.2, 13.2). The percentage of people who use illicit stimulants reporting past 6‐month use increased from 5.7% in 2013 to 7.3% in 2017 (APC 11.6; 95%CI: 0.2, 52.9) and from 5.4% in 2019 to 11.5% in 2024 (APC 17.8; 95%CI: 5.9, 41.1). The proportion of people who inject drugs reporting use varied between 7.2% and 17.5% over the short period studied (2020–2024). There were statistically significant increases in GHB‐related hospitalisations from 5.3 in 2012–13 to 19.1 per 100 000 people in 2022–23 (APC 19.0; 95%CI: 11.9, 31.1) and GHB‐related deaths from 0.02 in 2013 to 0.24 per 100 000 people in 2022 (APC 36.5; 95%CI: 27.2, 58.1). Treatment episodes also increased across the period, from 0.07 in 2012–13 to 6.0 episodes per 100 000 people in 2020–21 (APC 97.3; 95%CI: 83.5, 830.9), with no subsequent statistically significant change (8.4 per 100 000 people in 2022–23). Conclusions: Gamma‐hydroxybutyrate use, harms and treatment engagement increased in Australia from 2013 to 2024. These findings highlight a need to implement acceptable, tailored prevention and harm reduction strategies for key populations, and implement stronger monitoring efforts nationally and internationally.
- 21 October 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (1)
Rates and Clinical Characteristics of Self‐Administered Fatal Ketamine‐Related Poisoning in Australia, 2000–2025
Introduction: Recent years have seen marked increases in the non‐medical use of ketamine. We aimed to determine: (i) the population mortality rates of self‐administered fatal ketamine‐related poisoning cases in Australia, 2000–2022; (ii) the characteristics, toxicology and major autopsy findings of cases in Australia, 2000–2025; and (iii) changes in case characteristics across the period 2000–2025. Methods: Retrospective study of fatal ketamine‐related poisoning in Australia retrieved from the National Coronial Information System. Results: 118 cases were identified, 100 (84.7%) of which occurred after 2014. There was a significant upward trend in event rates between 2000 and 2022 (IRR = 1.16). The mean age was 36.2 years and 77.1% were male. The majority (72.9%) of poisonings were unintentional, in 19.5% the final route of ketamine administration was by injection, and a history of substance use problems was documented in 50.8%. There were no significant differences in these case characteristics across the study period. In 14 cases, the decedent was documented as being prescribed take‐home ketamine at the time of death and had consumed this medication. The median blood ketamine concentration was 0.20 mg/L (range 0.01–25.0), which did not significantly differ across time. Psychoactive drugs other than ketamine were present in all cases, most frequently hypnosedatives (68.6%) and opioids (62.7%), with a significant difference across time observed in the presence of hypnosedatives (OR 1.45). Cardiomegaly was diagnosed in 13.9% and cardiac fibrosis in 11.1%. Discussion and Conclusions: There has been a significant increase in self‐administered ketamine‐related poisoning deaths. Caution should be exercised in prescribing ketamine for self‐administration.
- 21 October 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (1)
Rates and Clinical Characteristics of Self‐Administered Fatal Ketamine‐Related Poisoning in Australia, 2000–2025
Introduction: Recent years have seen marked increases in the non‐medical use of ketamine. We aimed to determine: (i) the population mortality rates of self‐administered fatal ketamine‐related poisoning cases in Australia, 2000–2022; (ii) the characteristics, toxicology and major autopsy findings of cases in Australia, 2000–2025; and (iii) changes in case characteristics across the period 2000–2025. Methods: Retrospective study of fatal ketamine‐related poisoning in Australia retrieved from the National Coronial Information System. Results: 118 cases were identified, 100 (84.7%) of which occurred after 2014. There was a significant upward trend in event rates between 2000 and 2022 (IRR = 1.16). The mean age was 36.2 years and 77.1% were male. The majority (72.9%) of poisonings were unintentional, in 19.5% the final route of ketamine administration was by injection, and a history of substance use problems was documented in 50.8%. There were no significant differences in these case characteristics across the study period. In 14 cases, the decedent was documented as being prescribed take‐home ketamine at the time of death and had consumed this medication. The median blood ketamine concentration was 0.20 mg/L (range 0.01–25.0), which did not significantly differ across time. Psychoactive drugs other than ketamine were present in all cases, most frequently hypnosedatives (68.6%) and opioids (62.7%), with a significant difference across time observed in the presence of hypnosedatives (OR 1.45). Cardiomegaly was diagnosed in 13.9% and cardiac fibrosis in 11.1%. Discussion and Conclusions: There has been a significant increase in self‐administered ketamine‐related poisoning deaths. Caution should be exercised in prescribing ketamine for self‐administration.
Clinical characteristics of heroin overdose deaths among older adults in Australia, 2000–2025
Aims: To determine: (1) the circumstances of death and case characteristics of heroin‐related toxicity deaths aged ≥ 65 years in Australia, 2000–2025 and (2) the toxicological profile and major autopsy findings. Design: Retrospective study of fatal heroin overdose cases aged ≥65 years, 2000–2025. Setting: Australia‐wide. Cases: 59 cases were identified (65–69 years: 37, ≥70 years: 22), 51 (86.4%) male. Measurements: Circumstances of death, toxicology, major autopsy findings. Findings: No case occurred in the period 2000–2010, two between 2011 and 2015 and 57 between 2016 and 2025. All had documented histories of both substance use problems and injecting drug use. Cause of death was drug toxicity ( n = 36, 61.0%) or combined drug toxicity and disease ( n = 23, 39.0%), the majority being unintentional ( n = 49, 83.1%). The final route of administration was by injection in 58 cases. Amongst cases in which toxicology was available for inspection ( n = 52), the median free morphine concentration was 0.2 mg/l (0.0–3.7 mg/l), and 6‐acetylmorphine was present in 34 (65.4%). Psychoactive drugs other than heroin were present in 45 (86.5%) cases. Of autopsied cases, 18 (56.3%) had severe coronary artery disease, 14 (43.8%) cardiomegaly and 11 (34.4%) replacement fibrosis, indicating a past infarct. Five cases (15.6%) were diagnosed with acute bronchopneumonia, and chronic obstructive pulmonary disease was detected in 12 (37.5%). Conclusions: A new senior demographic of people who use heroin has emerged in Australia and is being reflected in overdose deaths. Systemic disease contributed to a large proportion of deaths between 2000 and 2025, and the toxicology is consistent with shorter survival times compared with younger cases.
Clinical characteristics of heroin overdose deaths among older adults in Australia, 2000–2025
Aims: To determine: (1) the circumstances of death and case characteristics of heroin‐related toxicity deaths aged ≥ 65 years in Australia, 2000–2025 and (2) the toxicological profile and major autopsy findings. Design: Retrospective study of fatal heroin overdose cases aged ≥65 years, 2000–2025. Setting: Australia‐wide. Cases: 59 cases were identified (65–69 years: 37, ≥70 years: 22), 51 (86.4%) male. Measurements: Circumstances of death, toxicology, major autopsy findings. Findings: No case occurred in the period 2000–2010, two between 2011 and 2015 and 57 between 2016 and 2025. All had documented histories of both substance use problems and injecting drug use. Cause of death was drug toxicity ( n = 36, 61.0%) or combined drug toxicity and disease ( n = 23, 39.0%), the majority being unintentional ( n = 49, 83.1%). The final route of administration was by injection in 58 cases. Amongst cases in which toxicology was available for inspection ( n = 52), the median free morphine concentration was 0.2 mg/l (0.0–3.7 mg/l), and 6‐acetylmorphine was present in 34 (65.4%). Psychoactive drugs other than heroin were present in 45 (86.5%) cases. Of autopsied cases, 18 (56.3%) had severe coronary artery disease, 14 (43.8%) cardiomegaly and 11 (34.4%) replacement fibrosis, indicating a past infarct. Five cases (15.6%) were diagnosed with acute bronchopneumonia, and chronic obstructive pulmonary disease was detected in 12 (37.5%). Conclusions: A new senior demographic of people who use heroin has emerged in Australia and is being reflected in overdose deaths. Systemic disease contributed to a large proportion of deaths between 2000 and 2025, and the toxicology is consistent with shorter survival times compared with younger cases.
- Open Access
- 1 July 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (6) , 1811-1815
Drugs and Drowning: The Toxicology of Adult Drownings in Baths and Hot Tubs in Australia, 2015–2024
Introduction: Drowning is the third leading cause of unintentional injury death. We aimed to determine the toxicology and circumstances of all adult drowning deaths that occurred in bath/hot tubs in Australia over the period 2015–2024.Methods: Retrospective study of all adult (≥ 15 years) drowning deaths in baths or hot tubs in Australia (1 January 2015–1 November 2024) retrieved from the National Coronial Information System (n = 195). In all cases the formal finding was based upon police, toxicology and forensic pathology reports.Results: There were 195 adult drownings in baths or hot tubs. The mean age was 54.9 years (range 15–98) and 127 (65.1%) were female. Most fatal (171, 87.7%) incidents occurred in a bath. In 113 (57.9%) cases proximal substance use was noted in the coronial conclusions as contributory. The majority (108, 55.4%) were unintentional, with 73 (37.4%) deemed intentional. A psychotropic drug was detected in the blood of 152/179 (84.9%), most commonly hypnosedatives (77/179, 43.0%) and alcohol (75/179, 41.9%). Amongst alcohol positive cases the mean blood alcohol concentration was 0.176 g/100 mL (range 0.010–0.537). In 33 (16.9%) there appeared to have been a medical episode, such as a seizure or a cardiovascular event, that preceded drowning, and a slip or fall in 17 (8.7%).Discussion and Conclusions: Substances were present in the majority of cases. The risk of drowning in such settings in the presence of drugs needs to be widely appreciated. Public campaigns that focus on the potential dangers of substance use in these settings would appear prudent.
- 1 July 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (6) , 1811-1815
Open AccessDrugs and Drowning: The Toxicology of Adult Drownings in Baths and Hot Tubs in Australia, 2015–2024
Introduction: Drowning is the third leading cause of unintentional injury death. We aimed to determine the toxicology and circumstances of all adult drowning deaths that occurred in bath/hot tubs in Australia over the period 2015–2024.Methods: Retrospective study of all adult (≥ 15 years) drowning deaths in baths or hot tubs in Australia (1 January 2015–1 November 2024) retrieved from the National Coronial Information System (n = 195). In all cases the formal finding was based upon police, toxicology and forensic pathology reports.Results: There were 195 adult drownings in baths or hot tubs. The mean age was 54.9 years (range 15–98) and 127 (65.1%) were female. Most fatal (171, 87.7%) incidents occurred in a bath. In 113 (57.9%) cases proximal substance use was noted in the coronial conclusions as contributory. The majority (108, 55.4%) were unintentional, with 73 (37.4%) deemed intentional. A psychotropic drug was detected in the blood of 152/179 (84.9%), most commonly hypnosedatives (77/179, 43.0%) and alcohol (75/179, 41.9%). Amongst alcohol positive cases the mean blood alcohol concentration was 0.176 g/100 mL (range 0.010–0.537). In 33 (16.9%) there appeared to have been a medical episode, such as a seizure or a cardiovascular event, that preceded drowning, and a slip or fall in 17 (8.7%).Discussion and Conclusions: Substances were present in the majority of cases. The risk of drowning in such settings in the presence of drugs needs to be widely appreciated. Public campaigns that focus on the potential dangers of substance use in these settings would appear prudent.
- Open Access
- 30 June 2025
- Published by Wiley in Journal of Forensic Sciences
- Vol. 70 (6) , 2434-2441
Characteristics and toxicology of adult deaths due to quetiapine toxicity in Australia, 2000–2024
Quetiapine is an atypical antipsychotic that has been associated with both intentional and unintentional deaths. We aimed to determine, stratified by intentionality: (1) The characteristics and circumstances of adult deaths attributed solely to quetiapine toxicity in Australia, 2000–2024; (2) The blood toxicology of cases for quetiapine and other drugs; and (3) The major autopsy findings for cardiovascular, lung, kidney, and liver disease. All cases of death aged ≥15 years attributed solely to quetiapine toxicity in Australia, 2000–2024, were retrieved from the National Coronial Information System. We identified 136 adult cases attributed solely to quetiapine toxicity. In 64.7% ( n = 88), the fatal poisoning was deemed intentional, unintentional in 19.9% ( n = 27), and of undetermined intent in 15.4% ( n = 21). The mean age was 42.4 years (range 15–69) and 58.1% ( n = 79) were male. A history of mental health problems was documented in 92.6% ( n = 126). The median quetiapine concentration was 12.0 mg/L (range 1.2–600.0), with that of intentional cases being twice that of unintentional cases (13.0 vs. 6.3 mg/L). Other psychotropic drugs not considered contributory to death were present in 73.0% ( n = 92) of cases, most commonly hypnosedatives (34.1%, n = 43) and antidepressants (33.3%, n = 42). Hearts were examined in 87 cases, of which 31.0% ( n = 27) were diagnosed with cardiovascular disease. Given these findings, screening patients prescribed quetiapine for suicide histories and ideation is prudent, as is monitoring cardiovascular disease. For forensic pathologists, the extent and nature of cardiovascular disease appear important for the formulation of death, and suicide should be borne in mind.
- 30 June 2025
- Published by Wiley in Journal of Forensic Sciences
- Vol. 70 (6) , 2434-2441
Open AccessCharacteristics and toxicology of adult deaths due to quetiapine toxicity in Australia, 2000–2024
Quetiapine is an atypical antipsychotic that has been associated with both intentional and unintentional deaths. We aimed to determine, stratified by intentionality: (1) The characteristics and circumstances of adult deaths attributed solely to quetiapine toxicity in Australia, 2000–2024; (2) The blood toxicology of cases for quetiapine and other drugs; and (3) The major autopsy findings for cardiovascular, lung, kidney, and liver disease. All cases of death aged ≥15 years attributed solely to quetiapine toxicity in Australia, 2000–2024, were retrieved from the National Coronial Information System. We identified 136 adult cases attributed solely to quetiapine toxicity. In 64.7% ( n = 88), the fatal poisoning was deemed intentional, unintentional in 19.9% ( n = 27), and of undetermined intent in 15.4% ( n = 21). The mean age was 42.4 years (range 15–69) and 58.1% ( n = 79) were male. A history of mental health problems was documented in 92.6% ( n = 126). The median quetiapine concentration was 12.0 mg/L (range 1.2–600.0), with that of intentional cases being twice that of unintentional cases (13.0 vs. 6.3 mg/L). Other psychotropic drugs not considered contributory to death were present in 73.0% ( n = 92) of cases, most commonly hypnosedatives (34.1%, n = 43) and antidepressants (33.3%, n = 42). Hearts were examined in 87 cases, of which 31.0% ( n = 27) were diagnosed with cardiovascular disease. Given these findings, screening patients prescribed quetiapine for suicide histories and ideation is prudent, as is monitoring cardiovascular disease. For forensic pathologists, the extent and nature of cardiovascular disease appear important for the formulation of death, and suicide should be borne in mind.